Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials

  • Authors:
    • Peng Fu
    • Yun-Song He
    • Qin Huang
    • Tao Ding
    • Yong-Cun Cen
    • Hong-Yang Zhao
    • Xiang Wei
  • View Affiliations

  • Published online on: March 10, 2016     https://doi.org/10.3892/mco.2016.816
  • Pages: 833-838
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

High-grade glioma is a richly neovascularized brain solid tumor with a poor prognosis. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial cell proliferation and angiogenesis, which has shown clinical efficacy in recurrent glioblastoma. MEDLINE/PubMed, EMBASE and Web of Science databases were searched for relevant studies that compared bevacizumab plus combined radiotherapy/temozolomide (RT/TMZ) with RT/TMZ alone in newly diagnosed glioblastoma (GBM). Of all the studies identified, three comparative trials were included in the systematic review. All three enrolling trials, including a total of 1,738 patients, investigated bevacizumab or placebo plus combined RT/TMZ treatment in glioblastoma. The result showed no increased overall survival (OS) (pooled hazard ratio (HR), 1.04; 95% confidence interval (CI), 0.84‑1.29; P=0.71) but increased progression‑free survival (HR, 0.74; 95% CI, 0.62‑0.88; P=0.0009). However, the two randomized double‑blind placebo‑control trials exemplified a high rate of adverse events of the bevacizumab compared with the placebo group while discrepant points were noted in term of quality-of-life outcome. Additionally, bevacizumab plus RT/TMZ did not increase the 6‑month survival rate [odd ratios (ORs), 0.65; 95% CI, 0.37‑1.13; P=0.13). Overall, addition of bevacizumab to radiotherapy-temozolomide treatment may be an effective therapy strategy for improving progression-free survival. OS and the 6‑month survival rate was not prolonged and there was questionable efficacy of bevacizumab on the quality-of-life of glioblastoma patients, thus further clinical trials should be performed.
View Figures
View References

Related Articles

Journal Cover

May 2016
Volume 4 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Fu, P., He, Y., Huang, Q., Ding, T., Cen, Y., Zhao, H., & Wei, X. (2016). Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials. Molecular and Clinical Oncology, 4, 833-838. https://doi.org/10.3892/mco.2016.816
MLA
Fu, P., He, Y., Huang, Q., Ding, T., Cen, Y., Zhao, H., Wei, X."Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials". Molecular and Clinical Oncology 4.5 (2016): 833-838.
Chicago
Fu, P., He, Y., Huang, Q., Ding, T., Cen, Y., Zhao, H., Wei, X."Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials". Molecular and Clinical Oncology 4, no. 5 (2016): 833-838. https://doi.org/10.3892/mco.2016.816